Citations (59)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Alper Sevinç, Metin Özkan, Ahmet Özet, Faysal Dane, Berna Öksüzoğlu, Abdurrahman Işıkdoğan, Feyyaz Özdemir, Doğan Uncu, Mahmut Gümüş, Türkkan Evrensel, Arzu Yaren, Oğuz Kara & Salim Başol Tekin. (2018) Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia. OncoTargets and Therapy 11, pages 419-426.
Read now
Read now
Alessandro Busca, Simone Cesaro, Luciana Teofili, Mario Delia, Chiara Cattaneo, Marianna Criscuolo, Francesco Marchesi, Nicola Stefano Fracchiolla, Caterina Giovanna Valentini, Francesca Farina, Roberta Di Blasi, Lucia Prezioso, Angelica Spolzino, Anna Candoni, Maria Ilaria del Principe, Luisa Verga, Annamaria Nosari, Franco Aversa & Livio Pagano. (2018) SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders. Expert Review of Hematology 11:2, pages 155-168.
Read now
Read now
Hideaki Yoshimura, Masaaki Hotta, Takahisa Nakanishi, Shinya Fujita, Aya Nakaya, Atsushi Satake, Tomoki Ito, Kazuyoshi Ishii & Shosaku Nomura. (2017) Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan. Journal of Blood Medicine 8, pages 5-12.
Read now
Read now
Liat Adar, Noa Avisar, Andreas Lammerich, Robert B Kleiman & Ofer Spiegelstein. (2015) A thorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects. Drug Design, Development and Therapy 9, pages 2653-2662.
Read now
Read now
Karl Welte. (2014) G-CSF: filgrastim, lenograstim and biosimilars. Expert Opinion on Biological Therapy 14:7, pages 983-993.
Read now
Read now
Alaa Bagalagel, Abdulaziz Mohammed, Karen MacDonald & Ivo Abraham. (2013) Clinical efficacy and safety of Tevagrastim® (XM02), a biosimilar recombinant human granulocyte colony-stimulating factor. Biosimilars 3, pages 55-62.
Read now
Read now
Ivo Abraham, Soba Tharmarajah & Karen MacDonald. (2013) Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors. Expert Opinion on Drug Safety 12:2, pages 235-246.
Read now
Read now
Alan Stewart, Philip Aubrey & Jonathan Belsey. (2010) Addressing the health technology assessment of biosimilar pharmaceuticals. Current Medical Research and Opinion 26:9, pages 2119-2126.
Read now
Read now
Articles from other publishers (51)
HyeJung Na, Sun-Hong Kwon, Kyung-Hwa Son, Youngsuk Baek, Jiye Kim & Eui-Kyung Lee. (2023) Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis. BioDrugs 37:2, pages 205-218.
Crossref
Crossref
Faraat Ali, Kamna Sharma & Asad Ali. (2022) Pegfilgrastim-Apgf (Nyvepria): Biosimilar USFDA Approval for the
Treatment of Chemotherapy-induced Febrile Neutropenia and Current
Updates on Clinical Trials. Current Drug Targets 23:9, pages 924-932.
Crossref
Crossref
Shruti Rastogi, Vivekanandan Kalaiselvan, Yousef A. Bin Jardan, Saima Zameer & Maryam Sarwat. (2022) Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database. Biology 11:2, pages 340.
Crossref
Crossref
Shruti Rastogi, Vivekananda Kalaiselvan, Sher Ali, Ajaz Ahmad, Sameer Ahmad Guru & Maryam Sarwat. (2021) Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis. Biology 10:10, pages 1069.
Crossref
Crossref
P.G. Cornes & M. Muenzberg. (2020) Commentary - A comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars and Intended Copy Biologics in treating chemotherapy associated febrile neutropenia. Toxicology and Applied Pharmacology 406, pages 115202.
Crossref
Crossref
Liese Barbier, Hans C. Ebbers, Paul Declerck, Steven Simoens, Arnold G. Vulto & Isabelle Huys. (2020) The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. Clinical Pharmacology & Therapeutics 108:4, pages 734-755.
Crossref
Crossref
Shruti Rastogi, Shatrunajay Shukla, Arvind Kumar Sharma, Maryam Sarwat, Pranay Srivastava, Tridiv Katiyar, Vivekanandan Kalaiselvan & Gyanendra Nath Singh. (2020) Towards a comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars in treating chemotherapy associated febrile neutropenia: Trends from decades of data. Toxicology and Applied Pharmacology 395, pages 114976.
Crossref
Crossref
Pamela Sue BeckerElizabeth A. GriffithsLaura M. AlwanKimo BachiashviliAnna BrownRita CoolPeter CurtinShira DinnerIvana GojoAshley HicksAvyakta KallamWajih Zaheer KidwaiDwight D. KlothEric H. KrautDaniel LandsburgGary H. LymanRyan MillerSudipto MukherjeeShiven PatelLia E. PerezAdam PoustRaajit RampalRachel RosovskyVivek RoyHope S. RugoSepideh ShayaniSumithira VasuMartha WadleighKelly WestbrookPeter Westervelt, Jennifer BurnsJennifer KellerLenora A. Pluchino. (2020) NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. Journal of the National Comprehensive Cancer Network 18:1, pages 12-22.
Crossref
Crossref
Pere Gascon, Andriy Krendyukov, Nicola Mathieson, Maja Natek & Matti Aapro. (2019) Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim. BioDrugs 33:6, pages 635-645.
Crossref
Crossref
Kamel Laribi, Delphine Badinand, Philippe Janoray, Khaled Benabed, Jean-Loup Mouysset, Elizabeth Fabre, Françoise Monchecourt & Rafik Diab. (2019) Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study. Supportive Care in Cancer 27:11, pages 4283-4292.
Crossref
Crossref
Yong Wang, Lin Chen, Fen Liu, Ning Zhao, Liyao Xu, Biqi Fu & Yong Li. (2019) Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network meta-analysis. Scientific Reports 9:1.
Crossref
Crossref
Noah Federman, Monica D. Dragomir, Zoryana Kizyma, Jelena Roganovic, Peter Bias, Andreas Lammerich, Zipi R. Ben Arie, Linglong Zou, Gerald Hoehn & Anton Buchner. (2019) A Phase 2, International, Multicenter, Open-label Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients With Solid Tumors Undergoing Myelosuppressive Chemotherapy. Journal of Pediatric Hematology/Oncology 41:7, pages 525-531.
Crossref
Crossref
Jichun Yang, Shuqing Yu, Zhirong Yang, Yusong Yan, Yao Chen, Hongmei Zeng, Fei Ma, Yanxia Shi, Yehui Shi, Zilu Zhang & Feng Sun. (2019) Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis. BioDrugs 33:4, pages 373-389.
Crossref
Crossref
Andriy Krendyukov & Martin Schiestl. (2019) Biosimilars in oncology: A decade of experience with granulocyte colony-stimulating factor and its implications for monoclonal antibodies. Critical Reviews in Oncology/Hematology, pages 102785.
Crossref
Crossref
Camille N. Abboud, Nicole Lang, Henry Fung, Andreas Lammerich, Anton Buchner, Patrick Liu, Udo Mueller, Ruth Pettengell, Ingo J. Diel, Hartmut Link & Ashutosh Pathak. (2018) Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors. Supportive Care in Cancer 27:7, pages 2569-2577.
Crossref
Crossref
Brian Chen, Sumimasa Nagai, James O. Armitage, Bartlett Witherspoon, Chadi Nabhan, Ashley C. Godwin, Y. Tony Yang, Anuhya Kommalapati, Sri Harsha Tella, Carlo DeAngelis, Dennis W. Raisch, Oliver Sartor, William J. Hrushesky, Paul S. Ray, Paul R. Yarnold, Bryan L. Love, LeAnn B. Norris, Kevin Knopf, Laura Bobolts, Joshua Riente, Stefano Luminari, Robert C. Kane, Shamia Hoque & Charles L. Bennett. (2019) Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. The Oncologist 24:4, pages 537-548.
Crossref
Crossref
Holly TrautmanErika SzaboElizabeth JamesBoxiong Tang. (2019) Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective. Journal of Managed Care & Specialty Pharmacy 25:1, pages 94-101.
Crossref
Crossref
Liang Li, Lian Ma, Sarah J. Schrieber, Nam Atiqur Rahman, Albert Deisseroth, Ann T. Farrell, Yaning Wang, Vikram Sinha & Anshu Marathe. (2018) Quantitative Relationship Between AUEC of Absolute Neutrophil Count and Duration of Severe Neutropenia for G-CSF in Breast Cancer Patients. Clinical Pharmacology & Therapeutics 104:4, pages 742-748.
Crossref
Crossref
Linglong Zou, Anton Buchner, Jodie A Field, Steve Barash & Patrick M Liu. (2018) Immunogenicity assessment of tbo-filgrastim in cancer patients receiving chemotherapy. Bioanalysis 10:15, pages 1221-1228.
Crossref
Crossref
Kazuo Tamura, Kazue Hashimoto & Kiyohiro Nishikawa. (2018) Clinical safety and efficacy of “filgrastim biosimilar 2” in Japanese patients in a post-marketing surveillance study. Journal of Infection and Chemotherapy 24:5, pages 363-369.
Crossref
Crossref
Isabel Puértolas, Alberto Frutos Pérez-Surio, María Aránzazu Alcácera, Raquel Andrés & María del Tránsito Salvador. (2017) Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients. European Journal of Clinical Pharmacology 74:3, pages 315-321.
Crossref
Crossref
Ross A. McKinnon, Matthew Cook, Winston Liauw, Mona Marabani, Ian C. Marschner, Nicolle H. Packer & Johannes B. Prins. (2018) Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review. BioDrugs 32:1, pages 27-52.
Crossref
Crossref
Foluso AgboolaPrabashni Reddy. (2017) Conversion from Filgrastim to Tbo-filgrastim: Experience of a Large Health Care System. Journal of Managed Care & Specialty Pharmacy 23:12, pages 1214-1218.
Crossref
Crossref
Serdal Korkmaz & Fevzi Altuntas. (2017) What is the role of biosimilar G-CSF agents in hematopoietic stem cell mobilization at present?. Transfusion and Apheresis Science 56:6, pages 795-799.
Crossref
Crossref
Xiao Jun Wang & Alexandre Chan. (2017) Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions. Current Oncology Reports 19:3.
Crossref
Crossref
Dae Hyun Yoo, Nenad Prodanovic, Janusz Jaworski, Pedro Miranda, Edgar Ramiterre, Allan Lanzon, Asta Baranauskaite, Piotr Wiland, Carlos Abud-Mendoza, Boycho Oparanov, Svitlana Smiyan, HoUng Kim, Sang Joon Lee, SuYeon Kim & Won Park. (2017) Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Annals of the Rheumatic Diseases 76:2, pages 355-363.
Crossref
Crossref
Linda K. S. Leung, Kevin Mok, Calvin Liu & Stephen L. Chan. (2016) What do oncologists need to know about biosimilar products?. Chinese Journal of Cancer 35:1.
Crossref
Crossref
Serdar Sivgin, Esen Karakus, Muzaffer Keklik, Gokmen Zararsiz, Musa Solmaz, Leylagul Kaynar, Bulent Eser, Mustafa Cetin & Ali Unal. (2016) Evaluation of the efficacy and safety of original filgrastim (Neupogen?), biosimilar filgrastim (Leucostim?) and Lenograstim (Granocyte?) in CD34+ peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors. Transfusion and Apheresis Science 54:3, pages 410-415.
Crossref
Crossref
Ruth Pettengell, Peter Bias, Udo Mueller & Nicole Lang. (2016) Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor. Supportive Care in Cancer 24:6, pages 2677-2684.
Crossref
Crossref
Hannah A. Blair & Lesley J. Scott. (2016) Tbo-Filgrastim: A Review in Neutropenic Conditions. BioDrugs 30:2, pages 153-160.
Crossref
Crossref
Ivetta Danylesko, Rina Sareli, Nira Bloom-Varda, Ronit Yerushalmi, Noga Shem-Tov, Avichai Shimoni & Arnon Nagler. (2016) Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation 22:2, pages 277-283.
Crossref
Crossref
Steven Trifilio, Zheng Zhou, John Galvin, Jessica L. Fong, Joanne Monreal & Jayesh Mehta. (2015) Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question. Clinical Transplantation 29:12, pages 1128-1132.
Crossref
Crossref
Belinda R. Avalos. (2015) Bring on the Biosimilars!. Biology of Blood and Marrow Transplantation 21:11, pages 1859-1860.
Crossref
Crossref
Mohammed M. Elayan, Justin G. Horowitz, Jose M. Magraner, Paul J. Shaughnessy & Carlos Bachier. (2015) Tbo-Filgrastim versus Filgrastim during Mobilization and?Neutrophil Engraftment for Autologous Stem Cell?Transplantation. Biology of Blood and Marrow Transplantation 21:11, pages 1921-1925.
Crossref
Crossref
Thomas J. SmithKari BohlkeGary H. LymanKenneth R. CarsonJeffrey CrawfordScott J. CrossJohn M. GoldbergJames L. KhatcheressianNatasha B. LeighlCheryl L. PerkinsGeorge SomloJames L. WadeAntoinette J. WozniakJames O. Armitage. (2015) Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology 33:28, pages 3199-3212.
Crossref
Crossref
Bradford R. Hirsch & Gary H. Lyman. (2014) Biosimilars: A cure to the U.S. health care cost conundrum?. Blood Reviews 28:6, pages 263-268.
Crossref
Crossref
J.J. Vehreschild, A. Böhme, O.A. Cornely, C. Kahl, M. Karthaus, K.-A. Kreuzer, G. Maschmeyer, S. Mousset, V. Ossendorf, O. Penack, M.J.G.T. Vehreschild & J. Bohlius. (2014) Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy—evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). Annals of Oncology 25:9, pages 1709-1718.
Crossref
Crossref
Hien K. Duong, Bipin N. Savani, Ed Copelan, Steven Devine, Luciano J. Costa, John R. Wingard, Paul Shaughnessy, Navneet Majhail, Miguel-Angel Perales, Corey S. Cutler, William Bensinger, Mark R. Litzow, Mohamad Mohty, Richard E. Champlin, Helen Leather, Sergio Giralt & Paul A. Carpenter. (2014) Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation 20:9, pages 1262-1273.
Crossref
Crossref
Steven Lucio. (2017) Clinical and Formulary Considerations for Biosimilars. Hospital Pharmacy 49:1_suppl, pages 6-12.
Crossref
Crossref
Pere Gasc?n, Hans Tesch, Karl Verpoort, Maria Sofia Rosati, Nello Salesi, Samir Agrawal, Nils Wilking, Helen Barker, Michael Muenzberg & Matthew Turner. (2013) Clinical experience with Zarzio? in Europe: what have we learned?. Supportive Care in Cancer 21:10, pages 2925-2932.
Crossref
Crossref
M Schmitt, X Xu, I Hilgendorf, C Schneider, K Borchert, D Gläser, M Freund & A Schmitt. (2013) Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors. Bone Marrow Transplantation 48:7, pages 922-925.
Crossref
Crossref
Serdar Sivgin, Esen Karakus, Leylagul Kaynar, Fatih Kurnaz, Cigdem Pala, Muzaffer Keklik, Gokmen Zararsiz, Musa Solmaz, Bulent Eser, Mustafa Cetin & Ali Unal. (2013) The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: A single center experience from Turkey. Transfusion and Apheresis Science 48:3, pages 315-320.
Crossref
Crossref
Walter Hinderer. 2012. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology
285
335
.
Patricia Gravel, Aarti Naik & Jean-Yves Le Cotonnec. (2012) Biosimilar rhG-CSFs: how similar are they?. Targeted Oncology 7:S1, pages 3-16.
Crossref
Crossref
Giovanna Andreola, Aleksandra Babic, Cristina Rabascio, Mara Negri, Giovanni Martinelli & Daniele Laszlo. (2011)
Plerixafor and Filgrastim XM02 (Tevagastrim
®
) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation
. European Journal of Haematology 88:2, pages 154-158.
Crossref
Crossref
George Morstyn. 2012. Twenty Years of G-CSF. Twenty Years of G-CSF
3
13
.
François Lefrère, Anne-Colette Brignier, Caroline Elie, Jean-Antoine Ribeil, Michael Bernimoulin, Charbel Aoun, Liliane Dal Cortivo, Richard Delarue, Olivier Hermine & Marina Cavazzana-Calvo. (2011) First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factor. Advances in Therapy 28:4, pages 304-310.
Crossref
Crossref
M.S. Aapro, J. Bohlius, D.A. Cameron, Lissandra Dal Lago, J. Peter Donnelly, N. Kearney, G.H. Lyman, R. Pettengell, V.C. Tjan-Heijnen, J. Walewski, Damien C. Weber & C. Zielinski. (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. European Journal of Cancer 47:1, pages 8-32.
Crossref
Crossref
D. Spoerl & Andreas J. Bircher. 2011. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
769
814
.
P. García Alfonso. (2010) Filgrastim biosimilar: desde el desarrollo al registro. Farmacia Hospitalaria 34, pages 19-24.
Crossref
Crossref
. (2009) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 18:11.
Crossref
Crossref